Many patients with Parkinson’s disease take a combination medication called levodopa/carbidopa to control their symptoms, but over time, experience “off” episodes in which the tremor, slowed movement, and difficulty walking that characterize the disorder occur.

Now the FDA has approved a Neurocrine Biosciences (NASDAQ: NBIX) drug intended to be taken along with levodopa/carbidopa to extend the therapy’s “on” time for patients.

About 50,000 people in the United States are diagnosed with Parkinson’s disease yearly. After Alzheimer’s disease, the condition is the second most common neurodegenerative disorder in the country.

The Neurocrine drug, opicapone (Ongentys), is part of a class of… Read more »